Advertisement
ACRV vs DNA
Which Stock Would AI Choose? Acrivon Therapeutics (ACRV) vs. Ginkgo Bioworks (DNA) Stock Comparison
Key Takeaways
- Two different bets on biology: ACRV is a clinical-stage precision oncology developer, while DNA is a synthetic biology and autonomous lab platform company.
- Revenue profile diverges sharply: ACRV has no product revenue yet, whereas DNA generates revenue but reported a roughly 49% year-over-year decline in its most recent quarter.
- Cash and funding contrast: ACRV held about $90 million in cash and investments as of mid-2026, while DNA held roughly $373 million with no bank debt.
- Sentiment is asymmetric: ACRV carries a predominantly "Strong Buy" analyst consensus, while DNA faces a mostly bearish-to-neutral analyst mix.
- Near-term catalysts: ACRV awaits a Phase 2b interim data readout, while DNA is focused on scaling and monetizing its Nebula autonomous lab platform.
- For deeper coverage, explore ACRV Major News and ACRV Today's Price Move, plus DNA Major News and DNA Today's Price Move.
- To see how automated systems are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two very different names operating under the broad biotechnology umbrella. ACRV, Acrivon Therapeutics, is a clinical-stage developer of precision oncology medicines, while DNA, Ginkgo Bioworks, is a synthetic biology platform company pivoting toward autonomous laboratories. Although both trade as speculative, growth-oriented equities, their business models, capital positions, and market sentiment differ meaningfully. This comparison is most relevant to investors and traders evaluating relative performance, risk profiles, and market positioning among small-cap biotechnology stocks, and to those weighing clinical catalysts against platform-scale commercialization narratives.
ACRV Overview and Recent Performance
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines matched to patients using its proprietary AP3 platform, a phosphoproteomics-based approach that identifies which tumors are likely to respond to a given drug. Its lead candidate, ACR-368 (prexasertib), is in a registrational-intent Phase 2b study in serous endometrial cancer, with a prespecified interim analysis expected in the second half of 2026. The company has also advanced ACR-2316, a WEE1/PKMYT1 inhibitor, into a randomized dose-expansion stage.
In recent weeks, ACRV has been supported by data presentations at major oncology conferences and steady pipeline progress. Financially, the company reported a narrower net loss and held roughly $90 million in cash and investments as of its most recent quarter, a runway it expects to fund operations into late 2027. With no product revenue, price behavior has been driven primarily by clinical milestones and analyst coverage, where the consensus skews toward "Buy" and "Strong Buy" ratings.
DNA Overview and Recent Performance
Ginkgo Bioworks is a synthetic biology company that has refocused its strategy on autonomous laboratory infrastructure, anchored by its Nebula system in Boston, alongside cloud lab and data services. In recent months, the company completed the divestiture of its biosecurity business into a new entity called Perimeter, a transaction that brought in roughly $60 million and left DNA as a shareholder while narrowing its operational focus.
Recent financial results reflected the transition. Revenue from continuing operations declined about 49% year over year in the most recent quarter, and the company reaffirmed full-year cash-burn guidance in the range of $125 million to $150 million. On the balance sheet, DNA ended its latest quarter with roughly $373 million in cash and no bank debt. Market sentiment remains cautious, with several analysts maintaining sell or neutral ratings and trimming price targets amid limited visibility into how quickly the autonomous lab strategy will monetize.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and watchlist of securities. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots section that highlights only the strategies best aligned with current market conditions. These bots range in approach from short-term momentum and swing trading to longer-horizon trend following, and many are backed by multi-year track records and detailed statistical profiles. For investors looking to benchmark automated positioning across names like ACRV and DNA, reviewing the Trending AI Robots page offers a practical, data-driven starting point.
Head-to-Head Comparison
The two companies sit at opposite ends of the biotech risk spectrum. ACRV is a pure-play, pre-revenue oncology developer whose value hinges on clinical trial outcomes and regulatory milestones. Its growth drivers are binary and event-driven, with the upcoming Phase 2b interim analysis acting as a central catalyst. DNA, by contrast, operates a commercial platform with existing revenue, but that revenue is contracting as the company pivots toward unproven autonomous lab adoption.
On capital resilience, DNA holds a substantially larger cash balance, though it also burns cash at a higher absolute rate. ACRV maintains a leaner balance sheet with a longer stated runway relative to its burn. In terms of market sentiment, analyst consensus is notably more constructive on ACRV, while DNA faces a predominantly cautious-to-bearish outlook. Sector exposure also differs: oncology drug development versus life-sciences automation and synthetic biology services.
Tickeron AI Verdict
Based on observable factors such as trend consistency, analyst positioning, and the clarity of near-term catalysts, Tickeron's AI would likely favor ACRV at present. The company's more constructive consensus ratings, focused clinical roadmap, and a defined data readout expected in the coming months provide a relatively clearer event-driven framework than DNA's longer-horizon, execution-dependent autonomous lab pivot. That said, this assessment is probabilistic rather than definitive: ACRV remains exposed to binary clinical risk, while DNA's larger cash position offers greater resilience against an extended commercialization timeline. Relative positioning can shift quickly as new data and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRV is a Hold and DNA is a Hold.
Momentum Indicator for ACRV turns negative, indicating new downward trend
ACRV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 30 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DNA sees its Stochastic Oscillator ascends from oversold territory
On November 04, 2026, the Stochastic Oscillator for DNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 62 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on DNA as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for DNA just turned positive on November 10, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.498). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ACRV | DNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 7 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| Advances ODDS (%) | 8 days ago 89% | 3 days ago 84% |
| Declines ODDS (%) | 2 days ago 88% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRV’s FA Score shows that 0 FA rating(s) are green while DNA’s FA Score has 0 green FA rating(s).
- ACRV’s FA Score: 0 green, 5 red.
- DNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRV’s TA Score shows that 4 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).
- ACRV’s TA Score: 4 bullish, 6 bearish.
- DNA’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACRV (@Biotechnology) experienced а -5.99% price change this week, while DNA (@Biotechnology) price change was +11.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ACRV is expected to report earnings on Nov 12, 2026.
DNA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACRV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | -0.63% | ||
| IMRX - ACRV | 51% Loosely correlated | +5.48% | ||
| ALLR - ACRV | 48% Loosely correlated | -3.49% | ||
| CRMD - ACRV | 43% Loosely correlated | -1.83% | ||
| DNA - ACRV | 41% Loosely correlated | -2.91% | ||
| SANA - ACRV | 38% Loosely correlated | -1.42% | ||
More | ||||
DNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -2.91% | ||
| TWST - DNA | 63% Loosely correlated | -2.37% | ||
| RXRX - DNA | 61% Loosely correlated | -6.70% | ||
| VCYT - DNA | 58% Loosely correlated | -7.18% | ||
| ABSI - DNA | 53% Loosely correlated | -7.69% | ||
| NTLA - DNA | 53% Loosely correlated | -7.76% | ||
More | ||||